Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade.
Hama N, Kobayashi T, Han N, Kitagawa F, Kajihara N, Otsuka R, Wada H, Lee HK, Rhee H, Hasegawa Y, Yagita H, Baghdadi M, Seino KI. Hama N, et al. Among authors: kajihara n. iScience. 2020 Sep 19;23(10):101584. doi: 10.1016/j.isci.2020.101584. eCollection 2020 Oct 23. iScience. 2020. PMID: 33205010 Free PMC article.
Erratum: Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade.
Hama N, Kobayashi T, Han N, Kitagawa F, Kajihara N, Otsuka R, Wada H, Lee HK, Rhee H, Hasegawa Y, Yagita H, Baghdadi M, Seino KI. Hama N, et al. Among authors: kajihara n. iScience. 2022 Jan 5;25(1):103713. doi: 10.1016/j.isci.2021.103713. eCollection 2022 Jan 21. iScience. 2022. PMID: 35028541 Free PMC article.
Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Kajihara N, Kobayashi T, Otsuka R, Nio-Kobayashi J, Oshino T, Takahashi M, Imanishi S, Hashimoto A, Wada H, Seino KI. Kajihara N, et al. Cancer Immunol Immunother. 2023 Apr;72(4):851-864. doi: 10.1007/s00262-022-03293-3. Epub 2022 Sep 14. Cancer Immunol Immunother. 2023. PMID: 36104597 Free PMC article.
Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI. Nakamura T, et al. Among authors: kajihara n. J Gynecol Oncol. 2023 May;34(3):e25. doi: 10.3802/jgo.2023.34.e25. Epub 2022 Dec 21. J Gynecol Oncol. 2023. PMID: 36603850 Free PMC article.
Autoimmune Polyglandular Syndrome Type 3 Complicated with IgG4-related Disease.
Murata Y, Haneda M, Miyakawa N, Nishida S, Kajihara N, Maeda S, Ono K, Hanatani S, Igata M, Takaki Y, Motoshima H, Kishikawa H, Araki E. Murata Y, et al. Among authors: kajihara n. Intern Med. 2024 Feb 1;63(3):425-431. doi: 10.2169/internalmedicine.1270-22. Epub 2023 Jun 21. Intern Med. 2024. PMID: 37344441 Free PMC article.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
65 results